Latest Medtech News
From smart-ring diagnostics and AI-native MSK care to pediatric cardiac devices and prostate-focused imaging, this week's MedTech funding highlights investor confidence in platforms that extend clinical monitoring beyond the hospital and into earlier, more targeted intervention.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like these. Subscribe to our Industry Insights for weekly coverage.
Happy Health raises $75M Series A to expand smart ring platform beyond sleep apnea
Cross Border Impact Ventures has raised $58M toward its second fund, continuing its focus on backing companies in women's and children's health. The firm is navigating a challenging fundraising climate, noting stronger investor appetite in the US and Europe compared to Canada.
CEO Dustin Freckleton: "What we've built in sleep is the foundation for a much bigger vision: continuously monitoring patients at home to detect disease earlier and give physicians the opportunity to intervene before it becomes more serious."
Cross Border Impact Ventures raises $58M for second fund backing women's and children's health
Cross Border Impact Ventures has raised $58M toward its second fund, continuing its focus on backing companies in women's and children's health. The firm is navigating a challenging fundraising climate, noting stronger investor appetite in the US and Europe compared to Canada.
Managing Partner Annie Thériault: “It targets ventures with a good line of sight to commercialization and regulatory approval,”
MaxQ Medical raises $31.5M Series A to advance ultrasound-guided prostate care platform
MaxQ Medical has closed a $31.5M Series A financing to advance its transurethral ultrasound imaging and tissue-selective therapy platform for prostate care, starting with BPH. The funds will support clinical evaluations already underway as the company works toward broader physician and patient adoption.
CEO Amir Tehrani: "This funding lets us continue the clinical evaluations already underway and move closer to giving physicians and their patients a better option."
Renata Medical raises $25M Series D to scale pediatric growth stent Minima
Renata Medical has closed a $25M Series D round to advance commercialization of its Minima growth stent for pediatric patients with congenital heart defects. The financing will support continued adoption of the device across congenital heart programs.
CEO and Co-Founder Dustin Armer: "Adoption of the Minima stent system has exceeded our expectations since commercial launch in 2024. The support and participation of Archimed is further validation of what we are building and of the growing opportunity to transform care for children with congenital heart disease."
AssistMe raises €6.5M to expand incontinence-monitoring platform across Europe and prepare US entry
AssistMe has raised €6.5M to expand its incontinence-monitoring care platform across Europe and prepare for a 2027 US market entry. The funding reflects the company's belief that care decisions are too often made on incomplete information — a gap its sensor-based platform is built to close.
CEO Julio Brandl (translated from Spanish): "AssistMe was founded because in the care sector, decisions are made every day based on incomplete information. With this new capital, we will now also bring alea to the United States."
Capitan Orthopedics closes oversubscribed seed round, bringing total funding to $4.1M
Capitan Orthopedics has closed an oversubscribed seed round, bringing total funding to $4.1M, ahead of its first in-human trial for its shoulder implant, expected in Q1 2027. The round adds to recent momentum following the company's FDA Breakthrough Device Designation.
CEO Chance W. Leonard: "I am extremely excited to announce that we have not only closed our Seed round, but have oversubscribed by over $1.1 million dollars. In addition to our recent receipt of FDA Breakthrough Device Designation, our team continues to reach milestone achievements at an accelerated pace."
Aisel Health raises €1.7M pre-seed to build an AI-powered operating system for psychiatry
Aisel Health has raised €1.7M in pre-seed funding to build an AI-powered operating system for psychiatry, designed to surface scattered patient history data for clinicians.
CEO Augusta Klingsten Peytz
AI Dock raises ¥260M in seed funding for AI-enhanced full-body scans
AI Dock has raised ¥260M in seed funding to develop AI-enhanced full-body scans for preventive medicine.
CEO Yuki Shimahara
Pulsenmore receives $1.27M grant to develop AI-guided home ultrasound program
Pulsenmore has received a $1.27M grant from the Israel Innovation Authority to develop its SmartScan AI home ultrasound guidance program, building an AI layer that spans from image acquisition through clinical workflow.
Founder and CEO Dr. Elazar Sonnenschein
Surgerix Oy closes €900K to advance real-time surgical visualization software for neurosurgery
Surgerix Oy has closed €900K to advance pre-clinical research on its real-time surgical visualization software for neurosurgery, aimed at de-risking the path to clinical adoption ahead of regulatory efforts in Europe and North America.
Founder and CEO Mikko Pitkänen: "This funding enables us to de-risk the path to clinical adoption. We're now positioned to conduct structured pre-clinical validation and strengthen our regulatory readiness for European and North American markets."
Fondaction and BDC invest in Icentia to accelerate cardiac arrhythmia monitoring rollout
Fondaction and BDC have invested in Icentia to accelerate the rollout of its CardioSTAT long-term cardiac arrhythmia monitoring solution, with the investors highlighting the company's device reconditioning and reuse model as a sustainability differentiator.
Alain Longpré, Fondaction's Deputy Head of Impact and Sustainable Investments: "Icentia also stands out for its responsible management of the lifecycle of its medical devices, particularly through the reconditioning and reuse of components. This approach reduces the environmental footprint and makes medical monitoring more accessible to the public."
Seed Healthcare leads strategic investment in Diadem to support US commercialization of Alzheimer's diagnostic
Seed Healthcare has led a strategic investment in Diadem to support US commercialization of its blood-based Alzheimer's diagnostic, AlzoSure Predict, as the company expands its presence in the US market.
CEO Paul Kinnon: “Seed's experience building healthcare businesses and supporting commercialization makes them the right partner as we expand our presence in the United States and continue advancing our platform.”
